Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Disease and Major Depressive Disorder
Summary
“Major Depressive Disorder is a common psychiatric condition that affects women at twice the rate as men and for which there remains a significant need for new treatment options for the more than 300 million people worldwide who are living with this disease. The funding announced today will allow us to advance all three programs into pivotal trials which, if successful, could help change the way we treat MDD and PD.” Dr. Kathleen Clarence-Smith, co-founder and Board Chair of CTC welcomed Javier Romero, Chairman and CEO of Chinalink. “Javier is committed to making investments in highly innovative companies that will help shape the 21st century, ranging from climate change to artificial intelligence to biotech. The company focuses on the rapid translation of therapeutic breakthroughs in neurosciences research that may help prevent and potentially cure central nervous system dysfunction. Chinalink´s vision has been to invest in highly innovative companies destined to help shape the 21st century from climate change to artificial intelligence to biotech.